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Acute myocardial infarction is primarily due to coronary atherosclerotic plaque rupture and subsequent 
thrombus formation. platelets play a key role in the genesis and progression of both atherosclerosis and 
thrombosis. Since platelets are anuclear cells that inherit their mRnA from megakaryocyte precursors 
and maintain it unchanged during their life span, gene expression profiling at the time of an acute 
myocardial infarction provides information concerning the platelet gene expression preceding the 
coronary event. in St-segment elevation myocardial infarction (SteMi), a gene-by-gene analysis of the 
platelet gene expression identified five differentially expressed genes: FKBP5, S100P, SAMSN1, CLEC4E 
and S100A12. The logistic regression model used to combine the gene expression in a STEMI vs healthy 
donors score showed an AUC of 0.95. The same five differentially expressed genes were externally 
validated using platelet gene expression data from patients with coronary atherosclerosis but without 
thrombosis. Platelet gene expression profile highlights five genes able to identify STEMI patients and 
to discriminate them in the background of atherosclerosis. consequently, early signals of an imminent 
acute myocardial infarction are likely to be found by platelet gene expression profiling before the 
infarction occurs.
Acute myocardial infarction is a sudden event that is fatal in approximately one-third of patients, with about half 
of the deaths occurring within one hour. It is frequently attributed to coronary atherosclerotic plaque rupture and 
the consequent exposure of thrombogenic substances that promote platelet activation/aggregation, the activation 
of coagulation and, ultimately, the formation of an intraluminal thrombus that limits coronary blood flow1,2. 
However, although plaque rupture or fissuring frequently occurs in atherosclerosis, only a small proportion of 
ruptured plaques results in thrombosis. Autopsy data show that a sizable proportion of the subjects who die sud-
denly of non-cardiac causes have fissured plaques without thrombosis in their coronary arteries3. The rupture of 
coronary atherosclerotic plaque is therefore much more frequent than thrombus formation. It has been suggested 
that individual reactivity to plaque rupture may play a causative role in provoking the clinical event of acute 
myocardial infarction4–8.
Platelets are key mediators of hemostasis that contribute to the genesis and progression of atherosclerosis, 
and the precipitation of an atherothrombotic event after plaque rupture1,2,9. Platelets are anuclear cells formed 
from the cytoplasm of megakaryocytes (MKs) and circulate in the blood stream for about 7–10 days10. Despite 
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the absence of a nucleus, platelets contain RNAs, including messenger RNA (mRNA), long non-coding RNA 
and micro-RNA, and protein synthesis machinery accounting for more than 9,000 transcripts in healthy human 
donors11–13. Platelet mRNA is primarily derived from MKs: indeed, genome-wide expression studies of platelets 
and MK-derived cultures from CD34 + hematopoietic progenitor cells, have shown that about half of the approx-
imately 10,000 transcripts present in MKs can also be found in platelets14,15.
Platelet transcriptome alterations have been associated with specific human phenotypes such as coronary 
artery disease16–18, atrial fibrillation19, essential thrombocythemia20, systemic lupus erythematosus21 and sickle 
cell anemia22. The transcriptional profiling of platelets provides information concerning the gene expression that 
precedes an acute coronary event without the confounding possibility of de novo gene transcription. This study 
was therefore designed to test the hypothesis that platelet transcriptome contains the gene signature of an immi-
nent myocardial infarction.
Results
The gene that showed the strongest evidence of differential expression between the ST-segment elevation myo-
cardial infarction (STEMI) and healthy donors (HD) groups (Table 1) was FKBP5 (odds ratio: 204.06; 95% 
confidence interval 12.11–15705.95; p = 0.0026), followed by S100P (odds ratio: 3.35; 95% confidence interval 
1.48–9.25; p = 0.0082), SAMSN1 (odds ratio: 2.76; 95% confidence interval 1.42–6.53; p = 0.0075), S100A12 
(odds ratio: 2.35; 95% confidence interval 1.51–4.52; p = 0.0017) and CLEC4E (odds ratio:1.97; 95% confidence 
interval 1.26–3.47; p = 0.0079) (Fig. 1, panel a and Supplemental Table 1). A logistic regression model based on 
the five genes was capable of discriminating the STEMI patients from HDs with an area under the curve (AUC) 
of 0.95 (95% confidence interval 0.62–1.00) (Fig. 2, panel a). These results were internally validated by means of a 
bootstrap analysis that took gene selection into account. Additionally, we found that the expression levels of these 
five genes were independent from the time of blood withdrawn (Supplemental Fig. 1). Moreover, we tested the 
correlation levels between the expression of each of the five identified genes and CK-MB and Troponin I circulat-
ing levels. No statistically significant correlation was found except for S100P vs CK-MB (p = 0.56, p = 0.0120) and 
S100P vs Troponin I (p = 0.5700, p = 0.0110) (Supplemental Fig. 2), in agreement with a previous study on a rat 
model with ischemia-reperfusion injury23.
The ability of the five identified genes to discriminate subjects with enhanced reactivity to plaque rupture was 
externally confirmed using data from a further 20 patients with stable coronary artery disease (SCAD), the pheno-
typically closest condition to STEMI (Fig. 1, panel b). The logistic model based on these five genes was capable of dis-
criminating the STEMI and SCAD groups with an AUC of 0.93 (95% confidence interval 0.60–1.00) (Fig. 2, panel b).
Discussion
Here, we first report five differentially expressed genes (DEGs) on platelet transcriptome able to identify STEMI 
patients from HD. It is worth noting that all 5 DEGs were already known to be associated with cardiovascular 
conditions: S100A12 with coronary artery disease (CAD) and atherosclerotic plaques24; FKBP5 with STEMI25; 
CLEC4E and SAMSN1 with atherosclerotic lesions26,27; and S100P with acute coronary syndrome (ACS)23 
(Table 2). Overall, analysis of platelet gene expression reveals quantitative differences that immediately precede 
the occurrence of an acute myocardial infarction.Indeed, our data and the existing literature16,23,24 strongly sug-
gested that S100 protein family28 is a relevant player in cardiovascular risk29 and thrombus formation both in 
mouse30 and ACS patients31. However, S100 protein family demonstrated a poor perfomance as a biomarker 
in emergency settings32,33. On the contrary, this panel of 5 DEGs allowed a successful sorting of cardiovascular 
events.
In fact, the simultaneous up-regulation of these five genes, which are known simultaneous up-regulation of 
these five genes, which are known to be associated with cardiovascular conditions, identified STEMI patients 
and, in a background of coronary atherosclerosis, discriminated those with or without thrombosis. A limitation 
of our study is the relatively small sample size, and we are aware that our five genes set has to be validated in larger 
population cohorts of STEMI subjects and in cohorts of subjects with different degrees of cardiovascular risk. 
We are also aware that our healthy donor controls could not be the best comparator due to confounding by 
medications. Non-ACS chronic CAD patients matched for age and medications might be a better comparator 
to further confirm our results. However, it is our opinion that the stringent inclusion criteria (i.e. blood samples 
processing within 6 hours; absence of pharmacological treatments before symptoms onset and sample collection) 
as well as exclusion criteria (as reported in the Methods Section, we excluded all the STEMI patients under 
anti-thrombotic/anti-coagulant treatment and/or anti-platelet drugs [except aspirin, which is mandatory based 
on current guidelines] before the time of hospital admission) adopted generated the solid evidence reported. Even 
if data from the literature reported that aspirin could affect mRNA and protein expression of megakaryocytes and 
platelets34–36, our results unequivocally distinguished STEMI patients from healthy donors (all without aspirin 
treatment) and from SCAD patients (all on aspirin treatment). Therefore, we believe that aspirin did not interfere 
with the concurrent differential expression of the five identified genes.
This is the first study demonstrating that platelets gene expression contains useful information to predict an 
unexpected clinical event such as MI. So far, no other biomarkers proved to be able to predict plaque rupture, 
the underlying mechanism of acute MI. The logical next step will be a prospective clinical validation in a larger 
population at high risk for MI and moreover, future studies are also needed to clarify whether the five identified 
genes have causative role or are simply markers of the acute event to happen. Notwithstanding these caveats, the 
translational relevance of our findings pre-dating myocardial infarction is evident per se and might well repre-
sent a valuable predictor for this still unpredictable disease and shed a light into the biological underpinning of 
acute myocardial infarction that precede current diagnostic tools and potentially lead to changes in the way we 
approach patients with suspected heart attack in the future.
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Methods
patient selection. Three groups of subjects were studied: (1) twenty patients with ST elevation myocar-
dial infarction (STEMI); (2) twenty healthy donor (HD); (3) twenty patient with stable coronary artery disease 
(SCAD).
All subjects were enrolled at the Cardiology Division of the Azienda Ospedaliero-Universitaria of Parma. 
This study was performed according to the Declaration of Helsinki, the protocol was approved by the Ethical 
Committee of Parma University Hospital and subjects were enrolled after written informed consent.
Between June 2014 and October 2015, we prospectively enrolled 20 patients with ST elevation myocardial 
infarction (STEMI) defined as typical chest pain with the following electrocardiographic criteria: a new ST seg-
ment elevation at the J point in two contiguous leads, with cut-off points of >0.1 mV in all leads other than leads 
V2-V3, for which the cut-off points were ≥0.2 mV in men aged ≥40 years, ≥0.25 mV in men aged <40 years, 
STEMI HD SCAD
Number of patients, n 20 20 20
Age, median (range) 65.5 (51–82) 62.5 (49–81) 63.5 (51–80)
Gender
Male, n (%) 15 (75) 15 (75) 15 (75)
Female, n (%) 5 (25) 5 (25) 5 (25)
Family history
n (%) 7 (35) 0 (0) 3 (15)
Hypertension
n (%) 11 (55) 0 (0) 17 (85)
Smoking
n (%) 10 (50) 0 (0) 3 (15)
Dyslipidemia
n (%) 9 (45) 0 (0) 11 (55)
Diabetes Mellitus
n (%) 5 (25) 0 (0) 7 (35)
Obesity
n (%) 2 (10) 0 (0) 3 (15)
ST elevation
Inferior- lateral, n (%) 3 (15) no no
Anterior, n (%) 9 (45) no no
Inferior, n (%) 7 (35) no no
Lateral, n (%) 1 (5) no no
Angiography
CX occlusion, n (%) 4 (20) n/a 1 (5)
LAD occlusion, n (%) 9 (45) n/a 10
RCA occlusion, n (%) 7 (35) n/a 1
CX, LAD 0 n/a 2
CX, RCA 0 n/a 1
LAD, RCA 0 n/a 1
CX, LAD, RCA 0 n/a 4
Thrombosis
n (%) 20 (100) n/a no
CK-MB, mean ± SD 172.39 ± 95.30 normal normal
Tn I, mean ± SD 48.44 ± 28.32 normal normal
Aspirin
n (%) 6 (30) 0 (0) 20 (100)
P2Y12 Inhibitors
n (%) 0 (0) 0 (0) 0 (0)
Anticoagulants
n (%) 0 (0) 0 (0) 0 (0)
Table 1. Clinical, electrocardiographic, and angiographic variables of the patients. Family history of ischemic 
heart disease in a first-degree relative before 55 years in men and before 65 years in women; ST elevation: 
location of ST elevation; CX: circumflex coronary artery; LAD: left anterior descending coronary artery; RCA: 
right coronary artery; Thrombosis: presence of coronary thrombosis at angiography; CK-MB: CK-MB peak in 
ng/mL; Tn-I: Troponin I peak in ng/ml. Aspirin: patients on treatment with aspirin; P2Y12 Inhibitors: patients 
on treatment with P2Y12 inhibitors; Anticoagulants: patients on treatment with anticoagulants n: number of 
patients. N/A: not applicable.
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or ≥0.15 mV in women37. Before coronary angiography, all of the patients underwent arterial blood sampling 
(50 mL) within one our from the hospital admission. For all STEMI patients, the time to chest pain/symptoms 
onset ranged from 1 to 6 hours before sample collection. The samples were collected before the administration of 
any anticoagulant or antiplatelet drugs (except acetylsalicylic acid given before hospital arrival). All blood sam-
ples have been processed within one hour of collection.
Each STEMI patient (Supplemental Table 2) was sex- and age-matched (±3 years) with a healthy donor (HD) 
(Supplemental Table 3) and a patient with stable coronary artery disease (SCAD) (Supplemental Table 4).
The HDs were defined as subjects without a previous history of cardiovascular diseases and without any risk 
factors for ischemic heart diseases. All the HD samples collection were planned within one-hour from medical 
examination. The HDs underwent venous blood sampling (50 mL), and all of the samples were processed within 
one hour of collection. The HDs were not taking any drugs (Supplemental Table 3).
SCAD was defined as a documented coronary artery stenosis of >70% in at least one epicardial main artery 
and documented inducible ischemia and/or symptoms without any characteristic of unstable disease38 (i.e. tro-
ponin elevation, rest angina, new-onset angina, recent onset of moderate-to-severe angina, or crescendo angina). 
All the SCAD samples collection were planned within one-hour from medical examination. The SCAD patients 
underwent venous blood sampling (50 mL), and all of the samples were processed within one hour of collection. 
At the time of sampling, all of the patients with SCAD were on aspirin and none of them were taking a P2Y12 
inhibitor or anticoagulant (Supplemental Table 4).
Patients characteristics and their cardiovascular risk factors are reported in Table 1.
Sample source and platelet purification. Citrate anti-coagulated blood samples (50 mL) were taken 
from each subject and collected in vacutainers (BD Vacutainer, Becton Dickinson, San Diego, CA) at a final 
sodium citrate concentration of 3.8%.
Leukocyte depletion was used to obtain highly purified platelets, as previously described39,40. The 
leucocytes-depleted platelets were treated with an appropriate amount of TRIzolTM (Invitrogen) for cell lysis and 
RNA cryopreservation.
Quantitative real-time polymerase chain reaction (pcR). RNA was extracted from leucocytes-depleted 
platelets using TRIzolTM (Invitrogen), as previously described39. The RNA was reverse-transcribed and 
semi-quantitative real-time RT-PCRs were performed to detect the expression levels of CLEC4E, FKBP5, SAMSN1, 
S100A12 and S100P using the SYBR Premix Ex Taq II (Takara, Shiga, Japan) and a LightCycler 480 (Roche, Basel, 
Figure 1. Gene expression values of the five identified genes. Panel a: Individual gene expression values in 
STEMI patients (red), and healthy subjects (green) with median values and interquartile ranges of the five 
identified genes. Panel b: Individual gene expression values in STEMI patients (red), and SCAD patients 
(orange) with median values and interquartile ranges of the five identified genes.
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Switzerland). ACTB (Actin Beta) and ITGA2B (Integrin, Alpha 2b, Platelet Glycoprotein IIb of IIb/IIIa Complex, 
Antigen CD41) were used as housekeeping genes; the reactions were performed in triplicate, and the expression 
data were analysed and rescaled using GeNorm software41 (Supplemental Fig. 3).
Microarray hybridisation. RNA was extracted using TRIzolTM (Invitrogen) in accordance with the man-
ufacturer’s protocol, quantified on a Nanodrop ND-100 spectrophotometer, and quality assessed by means of 
analysis on an Agilent 2200 TapeStation (Agilent Tehnologies, Palo Alto, CA). Fragmented biotin-labelled cDNA 
was synthesised using the GeneChip WT Pico kit (Affymetrix, Santa Clara, CA). Affymetrix gene chips (Human 
Transcriptome Array 2.0, Affymetrix, Santa Clara, CA) were hybridised with fragmented and biotin-labelled 
cDNA. The chips were scanned by an Affymetrix Gene Chip Scanner 3000 using Command Console Software. 
The experiment was quality controlled using Expression Console Software v 1.4.1.
Microarray data processing. The expression data obtained from the Affymetrix probe-sets (70,523) were 
processed using Expression Console software (Affymetrix, www.affymetrix.com) with the default parameters. 
The data are available at GEO, Accession No. GSE109048
Statistical analysis. The expression levels of the 10% most variably expressed genes42 were collected into a 
38 × 6,754 matrix whose rows corresponded to the individual samples and columns corresponded to the selected 
genes, plus a column for individual STEMI-HD status. Simple logistic regression models43 were used to test 
each of the 6,753 expression variables for any association with the STEMI vs HD indicator. There were 51 gene 
Figure 2. Receiver operating characteristic (ROC) curve for discriminating STEMI from HD and from SCAD. 
(a) The area under the ROC curve (AUC) of the capacity of the five identified genes to discriminate STEMI 
patients and HD (red line). AUC of 0.95 (95% confidence interval 0.62–1.00). (b) The area under the ROC curve 
(AUC) of the capacity of the five identified genes to discriminate STEMI and SCAD patients (red dotted line). 
AUC of 0.93 (95% confidence interval 0.60–1.00).
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expression variables with a p-value of <0.05 (Supplemental Table 4) and five with a p-value of <0.01. The later 
were considered for the subsequent stage of analysis, in which they acted as explanatory variables in a multiple 
logistic regression model for the log-odds ratio of the risk of STEMI vs HD. The model was internally validated 
by means of bootstrap resampling44,45. We then ran 30,000 iterations of a bootstrap procedure, each iteration 
involving resampling with the replacement of the rows of the original data matrix in such a way as to preserve the 
original matched structure, and analysed the simulated dataset using the same procedure as that applied to the 
original dataset. The 30,000 bootstrapped Area Under curve (AUC) statistics were used to calculate an empirical 
mean value and 95% confidence interval for the “true” AUC value. Finally, our logistic predictor of the risk of 
STEMI vs HD was assessed in terms of its ability to discriminate STEMI from SCAD as an external validation of 
the model. This involved the use of data from further patients with SCAD – the phenotypically closest condition 
to STEMI with documented coronary atherosclerosis but without thrombosis (Fig. 1, panel b). In this analysis, 
the logistic predictor was used with the gene-specific coefficients fixed at the values estimated on the basis of the 
STEMI vs HD analysis. The analyses were made using custom R-scripts and R-3.3.246.
Reticulated platelet analysis. Aliquots of whole blood were stained with thiazole orange (TO) and 
analysed by means of flow cytometry in order to identify reticulated platelets47–49, as previously described40 
(Supplemental Fig. 4).
For detailed methods see “Supplemental Material”.
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